These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16952920)

  • 1. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study.
    van Vark LC; Kardys I; Bleumink GS; Knetsch AM; Deckers JW; Hofman A; Stricker BH; Witteman JC
    Eur Heart J; 2006 Oct; 27(19):2346-52. PubMed ID: 16952920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
    Oei HH; van der Meer IM; Hofman A; Koudstaal PJ; Stijnen T; Breteler MM; Witteman JC
    Circulation; 2005 Feb; 111(5):570-5. PubMed ID: 15699277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
    Persson M; Hedblad B; Nelson JJ; Berglund G
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and risk of heart failure. The Rotterdam Study.
    Kardys I; Knetsch AM; Bleumink GS; Deckers JW; Hofman A; Stricker BH; Witteman JC
    Am Heart J; 2006 Sep; 152(3):514-20. PubMed ID: 16923423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
    van Oijen M; van der Meer IM; Hofman A; Witteman JC; Koudstaal PJ; Breteler MM
    Ann Neurol; 2006 Jan; 59(1):139-44. PubMed ID: 16278861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
    Li N; Li S; Yu C; Gu S
    Postgrad Med; 2010 Jul; 122(4):200-5. PubMed ID: 20675983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
    Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
    J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognosis of heart failure in the general population: The Rotterdam Study.
    Mosterd A; Cost B; Hoes AW; de Bruijne MC; Deckers JW; Hofman A; Grobbee DE
    Eur Heart J; 2001 Aug; 22(15):1318-27. PubMed ID: 11465964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
    Packard CJ
    Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.
    Güder G; Frantz S; Bauersachs J; Allolio B; Wanner C; Koller MT; Ertl G; Angermann CE; Störk S
    Circ Heart Fail; 2009 Nov; 2(6):563-71. PubMed ID: 19919981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
    Lavi S; McConnell JP; Rihal CS; Prasad A; Mathew V; Lerman LO; Lerman A
    Circulation; 2007 May; 115(21):2715-21. PubMed ID: 17502572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study.
    Brugts JJ; Knetsch AM; Mattace-Raso FU; Hofman A; Witteman JC
    Arch Intern Med; 2005 Dec 12-26; 165(22):2659-65. PubMed ID: 16344425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study.
    Kardys I; Oei HH; Hofman A; Oudkerk M; Witteman JC
    Atherosclerosis; 2007 Apr; 191(2):377-83. PubMed ID: 16678183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.